Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3548221 | 1.00 | FKBP1A (0.43) | FKBP1AALDH1A1NPC1RAB9APDK2 | |
| SCHEMBL5276983 | 0.93 | ALOX5 (0.48) | FKBP1AALDH1A1NPC1RAB9APDK2 | |
| SCHEMBL3542223 | 0.89 | ALDH1A1 (0.39) | FKBP1AALDH1A1ALOX5PTGS2PTGS1 | |
| SCHEMBL3542221 | 0.89 | ALDH1A1 (0.39) | FKBP1AALDH1A1ALOX5PTGS2PTGS1 | |
| SCHEMBL3544265 | 0.89 | FKBP1A (0.51) | FKBP1AALDH1A1NPC1RAB9A | |
| SCHEMBL3544267 | 0.89 | FKBP1A (0.51) | FKBP1AALDH1A1NPC1RAB9A | |
| SCHEMBL3547718 | 0.86 | FKBP1A (0.44) | FKBP1AALDH1A1NPC1RAB9APDK2 | |
| SCHEMBL3547715 | 0.86 | FKBP1A (0.44) | FKBP1AALDH1A1NPC1RAB9APDK2 | |
| SCHEMBL3544875 | 0.85 | ALDH1A1 (0.53) | FKBP1AALDH1A1NPC1RAB9APDK2 | |
| SCHEMBL3544878 | 0.85 | ALDH1A1 (0.53) | FKBP1AALDH1A1NPC1RAB9APDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1539744-A4 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARM INC (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | FKBP1A 3069/4885ALDH1A1 2309/4885NPC1 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.